An experimental drug by Eli Lilly significantly lowered Lp(a) levels, a risk factor for heart attacks and strokes. Further research is needed to confirm if reducing Lp(a) levels can prevent cardiovascular events. Other companies are also developing drugs targeting Lp(a) with promising results.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay